Markets / Mutual funds / Sectoral / Thematic
PGIM India Mutual Fund · Equity fund · Regular plan · IDCW
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. However, there is no assurance that the investment objective of the scheme will be achieved. The Scheme does not guarantee/ indicate any returns.
Bars: this plan; the thin mark is the Sectoral / Thematic average (regular plans, growth option). Over a year: yearly averages (CAGR). Past returns do not guarantee future returns. Information only, not investment advice.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | +1.6 | |||||||||||
| 2025 | -5.7 | -7.9 | +7.5 | +1.5 | +0.8 | +3.1 | +2.9 | -3.6 | -1.5 | +4.9 | +0.8 | -2.4 |
| 2026 | -4.9 | +7.6 | -4.4 | +6.5 | +4.0 | +7.0 | +5.9 | +3.7 | -3.9 | -1.2 | +3.3 |
Each month's change in NAV (the current month to the latest NAV).
Worked out from this plan's actual NAVs. SIP: invested on the first NAV of each month. Taxes and exit loads are not included. Past returns do not guarantee future returns. Information only, not investment advice.
| Share of fund | 30 Sept 2026 | 31 Aug 2026 | Change |
|---|---|---|---|
| Stocks held | 94.9% | 94.6% | +0.31 |
| Short positions | -0.1% | -0.3% | +0.21 |
| Cash & others | 5.1% | 5.4% | -0.31 |
| Top 10 stocks | 57.2% | 59.6% | -2.45 |
| Number of stocks | 31 | 31 | 0 |
Change is in percentage points. Bought more and cut back list stocks whose share of the fund moved by at least 0.25 points. A share can also move because the price changed, not only because the fund traded.
| Holding | % of fund |
|---|---|
| Divi's Laboratories Ltd. INE361B01024 | 10.36% |
| Sun Pharmaceutical Industries Ltd. INE044A01036 | 10.25% |
| Torrent Pharmaceuticals Ltd. INE685A01028 | 8.49% |
| Ajanta Pharma Ltd. INE031B01049 | 4.96% |
| Max Healthcare Institute Ltd. INE027H01010 | 4.71% |
| Dr. Lal Path Labs Ltd. INE600L01024 | 4.33% |
| Mankind Pharma Ltd. INE634S01028 | 4.04% |
| Manipal Health Enterprises Ltd. INE459N01021 | 3.68% |
| Navin Fluorine International Ltd. INE048G01026 | 3.24% |
| Abbott India Ltd. INE358A01014 | 3.12% |
| Krishna Inst of Medical Sciences Ltd. INE967H01025 | 2.99% |
| Rubicon Research Ltd. INE506V01022 | 2.99% |
| Neuland Laboratories Ltd. INE794A01010 | 2.91% |
| Aster DM Quality Care Ltd. INE914M01019 | 2.56% |
| Sai Life Sciences Ltd INE570L01029 | 2.54% |
| ICICI Lombard General Insurance Co. Ltd. INE765G01017 | 2.10% |
| Cipla Ltd. INE059A01026 | 2.04% |
| Zydus Lifesciences Ltd. INE010B01027 | 2.04% |
| Lupin Ltd. INE326A01037 | 1.93% |
| IPCA Laboratories Ltd. INE571A01038 | 1.92% |
| Dr Agarwal's Eye Hospital Ltd. INE934C01018 | 1.86% |
| Anthem Biosciences Ltd. INE0CZ201020 | 1.81% |
| Global Health Ltd. INE474Q01031 | 1.52% |
| Gland Pharma Ltd. INE068V01023 | 1.50% |
| Jupiter Life Line Hospitals Ltd. INE682M01020 | 1.46% |
| Fortis Healthcare Ltd. INE061F01013 | 1.46% |
| Symbiotec Pharmalab Ltd. INE899I01028 | 1.10% |
| Lenskart Solutions Ltd. INE956O01016 | 0.99% |
| Molbio Diagnostics Ltd. INE869T01028 | 0.80% |
| Orchid Pharma Ltd. INE191A01027 | 0.79% |
| Sagility Ltd. INE0W2G01015 | 0.40% |
| Holding | % of fund |
|---|---|
| Net Receivables / (Payables) | -0.13% |
| Holding | % of fund |
|---|---|
| Clearing Corporation of India Ltd. | 5.24% |
From the fund house's monthly portfolio (pgimindia.com), as on 30 Sept 2026. Percentages are of the fund's net assets; short positions are negative. Published about ten days after each month ends.
Volatility: how much the NAV moves, as a yearly figure (higher = bumpier). Worst fall: the biggest drop from a high, in the NAV history we hold (from 13 Dec 2024).
| Fund size (average AUM, July - September 2026) | ₹118 cr across all plans · this plan ₹0.14 cr |
| Fund house | PGIM India Mutual Fund |
| Category | Equity · Sectoral / Thematic |
| Plan | Regular |
| Option | IDCW |
| Expense ratio (TER) | Direct 0.98% · Regular 2.65% (6 Nov 2026) |
| Exit load | For Exits within 90 days from date of allotment of units: 0.50%; For Exits beyond 90 days from date of allotment of units: NIL. |
| Minimum investment | ₹5,000 · additional ₹1,000 |
| Scheme code (AMFI) | 153037 |
| ISIN | INF663L01Z60 |
| NAV date | 6 Nov 2026 |
Scheme details from the fund's scheme summary document filed with AMFI; expense ratios from AMFI's daily filings.
| Plan | NAV | 1 year |
|---|---|---|
| Direct · Growth | ₹12.5000 | +22.07% |
| Regular · Growth | ₹12.1000 | +20.04% |
| Regular · IDCW | ₹12.1000 | +20.04% |
| Fund | 1 year | 3 years (a year) |
|---|---|---|
| Nippon India Taiwan Equity Fund | +37.70% | +40.44% |
| HDFC Defence Fund | +19.63% | +33.69% |
| HDFC Pharma and Healthcare Fund | +26.81% | +30.17% |
| SBI HEALTHCARE OPPORTUNITIES FUND | +21.11% | +24.39% |
| HDFC Transportation and Logistics Fund | +8.74% | +23.82% |
| UTI - Healthcare Fund | +17.70% | +23.50% |
| Mirae Asset Healthcare Fund | +22.57% | +23.40% |
| BANK OF INDIA MANUFACTURING & INFRASTRUCTURE FUND | +16.15% | +22.19% |
All Sectoral / Thematic funds ranked › · Compare with others ›
Information only, not investment advice.
₹12.5000 as of 6 Nov 2026, from AMFI's official NAV data.
1 year: 22.07%
Both invest in the same portfolio. Direct plans are bought straight from the fund house and pay no distributor commission, so their expenses are lower and their NAV grows slightly faster.